Sponsor & Developer Portfolio
CureVac
Clinical development pipeline, platform architecture, and registered trial tracking for CureVac vaccine candidates.
4
Candidates
4
Target Diseases
6
Linked Studies
Development Phase Distribution
Discontinued / Inactive: 4
Platform Technologies
mRNA: 2 Biological (unspecified platform): 2
Target Pathogens & Indications
COVID-19 Non-Small Cell Lung Carcinoma Prostate Carcinoma Squamous NSCLC
Vaccine Pipeline Candidates (4)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-cv09070101-mrna-vaccine-cvhnlc-50-g-curevac
CV09070101 mRNA vaccine (CVHNLC) 50 µg
Target: Squamous NSCLC
Platform: mRNA
Key Milestone: Primary completion (most advanced trial): 2029-12-31 (registry estimate)
Discontinued / Inactive
ctgov-cv9104-curevac
CV9104
Target: Prostate Carcinoma
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2016-04 (registry estimate)
Discontinued / Inactive
ctgov-cv9202-curevac
CV9202
Target: Non-Small Cell Lung Carcinoma
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2016-07 (registry estimate)
Discontinued / Inactive
ctgov-cvncov-vaccine-curevac
CVnCoV Vaccine
Target: COVID-19
Platform: mRNA
Key Milestone: Primary completion (most advanced trial): 2022-01 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.